Investigating the Effects of Social Stress on Brain Imaging (SSBI)

November 25, 2025 updated by: Massachusetts Institute of Technology
The purpose of this study is to examine whether experiencing a social stressor prior to the collection of neuroimaging measures is associated with differences in brain activation in healthy participants.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Using a randomized, parallel-group study design, this scientific investigation will examine the effect that experiencing the Trier Social Stress Test (TSST), the gold-standard for ethically inducing stress in a controlled laboratory setting, may have on neuroimaging measures of anxiety in healthy subjects. The study will enroll 50 healthy subjects who will be randomized to either experience the TSST or watch a nature film prior to undergoing task-based neuroimaging measures of emotional processing and self-referential processing using functional magnetic resonance imaging (fMRI).

This study will be conducted primarily at Massachusetts Institute of Technology with research and clinical support from Massachusetts General Hospital.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Massachusetts
      • Cambridge, Massachusetts, United States, 02139
        • Recruiting
        • Massachusetts Institute of Technology
        • Contact:
        • Principal Investigator:
          • John Gabrieli, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Ability and willingness to provide written informed consent.
  • Sufficiently fluent in English to participate in the trial.
  • Between 18-55 years of age (inclusive).
  • Right-hand dominant.
  • Current medications are stable for past 30 days (no changes to dose or frequency).
  • Negative result on pregnancy test (if female).
  • Negative result on urine drug screening.
  • Liebowitz Social Anxiety Scale (LSAS <30).

Exclusion Criteria:

  • History of bipolar disorder, schizophrenia, psychosis, delusional disorders.
  • History of eating disorder within past 6 months.
  • History of any traumatic brain injury.
  • Currently diagnosed with diabetes mellitus.
  • Presence of severe medical illness that would prevent completion of study procedures.
  • Presence of significant neurological illness or cognitive dysfunction (e.g.; seizures, dementia).
  • History of substance use disorder within past 6 months (other than nicotine and caffeine).
  • Use of any cannabis-containing products in past 30 days (CBD or THC).
  • Use of benzodiazepines in past 2 weeks.
  • Use of alpha- or beta-blockers in the past week.
  • History of claustrophobia.
  • Contraindications for MRI (e.g.; shrapnel).
  • Presence of any other medical condition that, in the investigator's opinion, may interfere with the study procedures.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Film + TSST
Nature Film + Trier Social Stress Test (TSST)
Participants randomized to the TSST arm will experience the Trier Social Stress Test.
No Intervention: Film Only (No-TSST)
Nature Film Only

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Differences in fMRI BOLD Response
Time Frame: 45 minutes after TSST
Patterns of brain activation measured as blood-oxygenation-level dependent (BOLD) signals will be assessed using 3.0 Tesla (3T) functional magnetic resonance imaging (fMRI). Several exploratory imaging paradigms, including the emotional face-matching task (EFMT) and the self-referential comment task (SRCT), will be used to examine differences between participants who experience the TSST and those who do not.
45 minutes after TSST

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Acute Subjective Anxiety
Time Frame: -180 minutes, -15 minutes, -5 minutes, +10 minutes, +20 minutes, +30 minutes
Subjective anxiety will be assessed with a modified Visual Analog Mood Scale (VAMS) which utilizes a vertical 100 millimeter (mm) bipolar visual scale between two opposing moods consisting of the following word pairs: calm-excited, relaxed-tense, and tranquil-troubled. Total subjective anxiety for each timepoint will be the average distance from the top for the three-question battery. VAMS will be assessed 180 minutes before start of TSST, 15 minutes before start of TSST, 5 minutes before start of TSST during the Anticipation phase, after the Stress Procedures (+10 minutes after start of TSST), after 5 minutes in the Recovery Phase (+20 minutes after start of TSST), and 15 minutes after start of the Recovery Phase (+30 minutes after start of TSST).
-180 minutes, -15 minutes, -5 minutes, +10 minutes, +20 minutes, +30 minutes
Differences in Salivary Alpha Amylase
Time Frame: -180 minutes, -15 minutes, -5 minutes, +10 minutes, +20 minutes, +30 minutes
Physiological stress will be assessed indirectly with salivary alpha amylase (sAA) activity which is regulated by the sympathetic branch of the autonomic nervous system. Samples will be collected using the SalivaBio Oral Swab (SOS) from Salimetrics. Participants will place the SOS in their mouth for 1-2 minutes at each timepoint to collect saliva. sAA will be assessed 180 minutes before start of TSST, 15 minutes before start of TSST, 5 minutes before start of TSST during the anticipation phase, after the Stress Procedures (+10 minutes after start of TSST), after 5 minutes in the Recovery Phase (+20 minutes after start of TSST), and 15 minutes after start of the Recovery Phase (+30 minutes after start of TSST).
-180 minutes, -15 minutes, -5 minutes, +10 minutes, +20 minutes, +30 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: John Gabrieli, PhD, Massachusetts Institute of Technology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 17, 2025

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

November 1, 2026

Study Registration Dates

First Submitted

October 19, 2022

First Submitted That Met QC Criteria

October 19, 2022

First Posted (Actual)

October 24, 2022

Study Record Updates

Last Update Posted (Estimated)

December 3, 2025

Last Update Submitted That Met QC Criteria

November 25, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2206000689

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All data, code, and materials used in the analyses will be made available upon request by John Gabrieli and Massachusetts Institute of Technology after scientific review and a completed data use agreement/material transfer agreement beginning one year after publication of the results. Any requests should be submitted to John Gabrieli at gabrieli@mit.edu.

IPD Sharing Time Frame

Data will become available beginning one year after publication of the results.

IPD Sharing Access Criteria

Data will be provided pending a scientific review and a completed data use agreement/material transfer agreement. Requests should be submitted to John Gabrieli at gabrieli@mit.edu.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Social Stress

Clinical Trials on Trier Social Stress Test (TSST)

Subscribe